| 李双双,王 萍,李 超,李 娜,张 怡.老年非小细胞肺癌患者全身免疫-炎症指数与化疗预后的相关性分析[J].现代生物医学进展英文版,2022,(21):4112-4116. |
| 老年非小细胞肺癌患者全身免疫-炎症指数与化疗预后的相关性分析 |
| Correlation Analysis of Systemic Immune-inflammatory Index and Chemotherapy Prognosis in Elderly Patients with Non-small Cell Lung Cancer |
| Received:May 05, 2022 Revised:May 29, 2022 |
| DOI：10.13241/j.cnki.pmb.2022.21.020 |
| 中文关键词: 老年非小细胞肺癌 化疗预后 全身免疫-炎症指数 |
| 英文关键词: Non-small cell lung cancer Prognosis of chemotherapy Systemic immune-inflammation index |
| 基金项目:陕西省重点研发计划项目（2021SF-312） |
|
| Hits: 1014 |
| Download times: 421 |
| 中文摘要: |
| 摘要 目的：探讨老年非小细胞肺癌患者全身免疫-炎症指数与化疗预后的相关性。方法：回顾性选择2018年1月至2020年5月确诊的老年非小细胞肺癌患者60例。收集60例老年非小细胞肺癌患者的年龄、性别、吸烟、病理分型、病理分期、入院的血红蛋白、C反应蛋白、乳酸脱氢酶、神经元特异性烯醇化酶、D二聚体、癌胚抗原、中性粒细胞计数、血小板计数、淋巴细胞计数、单核细胞计数等指标。（1）比较不同低全身免疫-炎症指数老年非小细胞肺癌患者的临床特征资料；（2）计算高全身免疫-炎症指数与低全身免疫-炎症指数组的中位无进展生存期；（3）Cox单因素分析模型分析老年非小细胞肺癌患者化疗中位无进展生存期的影响因素；（4）分析老年非小细胞肺癌患者化疗预后与全身免疫-炎症指数、肿瘤分期、淋巴细胞计数、癌胚抗原的相关性。结果：高、低全身免疫-炎症指数两组在肿瘤分期、血红蛋白、C反应蛋白、乳酸脱氢酶、中性粒细胞计数、血小板计数、单核细胞计数、淋巴细胞计数、D二聚体、癌胚抗原对比上有统计学意义（P<0.05）。低全身免疫-炎症指数组的化疗中位无进展生存期明显优于高全身免疫-炎症指数组（P<0.05）。Cox多因素分析结果表明，肿瘤分期在Ⅲ~Ⅳ期、淋巴细胞计数<1.1×109/L、癌胚抗原≥1 ng/mL、全身免疫-炎症指数≥18.172是老年非小细胞肺癌患者化疗中位无进展生存期的独立危险因素（P<0.05）。Sperman相关性分析结果表明，老年非小细胞肺癌患者化疗预后与全身免疫-炎症指数呈正相关（r=0.525，P=0.038）。结论：全身免疫-炎症指数是影响老年非小细胞肺癌患者化疗预后的独立危险因素，其升高则提高预后患者的预后不良。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the correlation between systemic immune-inflammation index and chemotherapy prognosis in elderly patients with non-small cell lung cancer. Methods: 60 elderly patients with NSCLC diagnosed from January 2018 to May 2020 were retrospectively selected. 60 cases of elderly with non-small cell lung cancer of the age, sex, smoking, pathological classification, pathologic stage, admission of hemoglobin, c-reactive protein and lactate dehydrogenase, neuron specific enolization enzyme, D dimer, carcinoembryonic antigen, neutrophil count, platelet count, lymphocyte count, mononuclear cell count were collected. (1) The clinical characteristics of elderly NSCLC patients with different low systemic immune-inflammatory indexes were compared; (2) Median progression-free survival was calculated in the high and low systemic immune-inflammation index groups; (3) The influencing factors of median chemotherapy progression-free survival in elderly patients with NSCLC was analyzed by Cox univariate analysis model; (4) The correlation between chemotherapy prognosis and systemic immune-inflammatory index, tumor stage, lymphocyte count and carcinoembryonic antigen in elderly patients with NON-small cell lung cancer were analyzed. Results: There were statistically significant differences in tumor stage, hemoglobin, C-reactive protein, lactate dehydrogenase, neutrophil count, platelet count, monocyte count, lymphocyte count, D dimer and carcinoembryonic antigen in two groups with high and low systemic immune-inflammation index (P<0.05). The median progression-free survival of chemotherapy in the low systemic immune-inflammation index group was better than that in the high systemic immune-inflammation index group(P<0.05). Cox multivariate analysis showed that tumor stage ⅲ ~ⅳ, lymphocyte count<1.1×109/L, carcinoembryonic antigen≥1 ng/mL and systemic immune-inflammatory index≥18.172 were independent risk factors for progress-free survival in elderly patients with NSCLC(P<0.05). Sperman correlation analysis showed that chemotherapy prognosis was positively correlated with systemic immune-inflammatory index (r=0.525, P=0.038) in elderly patients with NSCLC. Conclusion: Systemic immune-inflammation index is an independent risk factor affecting the prognosis of elderly patients with non-small cell lung cancer after chemotherapy, and which increase can improve the poor prognosis of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
